Bu öğeden alıntı yapmak, öğeye bağlanmak için bu tanımlayıcıyı kullanınız: http://hdl.handle.net/11452/30987
Başlık: Utilization of statins and LDL-cholesterol target attainment in Turkish patients with type 2 diabetes-a nationwide cross-sectional study (TEMD dyslipidemia study)
Yazarlar: Bayram, Fahri
Sönmez, Alper
Haymana, Cem
Sabuncu, Tevfik
Dizdar, Oğuzhan Sıtkı
Gurkan, Eren
Çarlıoğlu, Ayşe Kargılı
Agbaht, Kemal
Özdemir, Didem
Demirci, İbrahim
Barçin, Cem
Salman, Serpil
Tetiker, Tamer
Balcı, Mustafa Kemal
Kebapçı, Nur
Yumuk, Volkan
Toth, Peter P.
Satman, İlhan
Bursa Uludağ Üniversitesi/Tıp Fakültesi/Endokrinoloji ve Metabolizma Anabilim Dalı.
Ersoy, Canan
AAH-8861-2021
6701485882
Anahtar kelimeler: Biochemistry & molecular biology
Nutrition & dietetics
Dyslipidemia
Type 2 diabetes mellitus
Lipid-lowering treatments
Physicians’
Low-density lipoprotein cholesterol target attainment
Statin cessation
Attitudes
Physician inertia
Density-lipoprotein cholesterol
Lipid-modifying theraphy
Cardiovascular-risk
Gender-differences
Goal attainment
Real-world
Management
Disease
Guidelines
Complications
Yayın Tarihi: 11-Kas-2020
Yayıncı: BMC
Atıf: Bayram, F. vd. (2020) ."Utilization of statins and LDL-cholesterol target attainment in Turkish patients with type 2 diabetes-a nationwide cross-sectional study (TEMD dyslipidemia study)". Periodica Mathematica Hungarica, 80(1), 74-80.
Özet: Background Attaining acceptable levels of LDL Cholesterol (LDL-C) significantly improves cardiovascular (CV) outcomes in patients with type 2 diabetes mellitus (T2DM). The LDL-C target attainment and the characteristics of patients attaining these targets were investigated in this study. Furthermore, the reasons for not choosing statins and the physicians' attitudes on the treatment of diabetic dyslipidemia were also examined. Methods A nationwide, cross-sectional survey was conducted in tertiary centers for diabetes management. Adult patients with T2DM, who were under follow-up for at least a year in outpatient clinics, were consecutively enrolled for the study. LDL-C goals were defined as below 70 mg/dL for patients with macrovascular complications or diabetic nephropathy, and below 100 mg/dL for other patients. Data about lipid-lowering medications were self-reported. Results A total of 4504 patients (female: 58.6%) were enrolled for the study. The mean HbA1c and diabetes duration was 7.73 +/- 1.74% and 10.9 +/- 7.5 years, respectively. The need for statin treatment was 94.9% (n = 4262); however, only 42.4% (n = 1807) of these patients were under treatment, and only 24.8% (n = 448) of these patients achieved LDL-C targets. The main reason for statin discontinuation was negative media coverage (87.5%), while only a minority of patients (12.5%) mentioned side effects. Physicians initiated lipid-lowering therapy in only 20.3% of patients with high LDL-C levels. It was observed that the female gender was a significant independent predictor of not attaining LDL-C goals (OR: 0.70, 95% CI: 0.59-0.83). Conclusions Less than 50 % of patients with T2DM who need statins were under treatment, and only a quarter of them attained their LDL-C targets. There exists a significant gap between the guideline recommendations and the real-world evidence in the treatment of dyslipidemia in T2DM.
URI: https://doi.org/10.1186/s12944-020-01408-2
https://lipidworld.biomedcentral.com/articles/10.1186/s12944-020-01408-2
http://hdl.handle.net/11452/30987
ISSN: 1476-511X
Koleksiyonlarda Görünür:PubMed
Scopus
Web of Science

Bu öğenin dosyaları:
Dosya Açıklama BoyutBiçim 
Ersoy_vd_2020.pdf1.45 MBAdobe PDFKüçük resim
Göster/Aç


Bu öğe kapsamında lisanslı Creative Commons License Creative Commons